Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission by Balazs, A. B. et al.
POSTER PRESENTATION Open Access
Vectored immunoprophylaxis protects humanized
mice from mucosal HIV transmission
AB Balazs1*, J Chen1, C Hong1, S Ouyang1, D An2, D Baltimore1
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
Recently, a number of antibodies capable of broadly neu-
tralizing HIV have been isolated from HIV infected
patients, stimulating efforts to develop vaccines capable of
eliciting their production in naive individuals. As an alter-
native to vaccination, we recently described vectored
immunoprophylaxis (VIP) as an approach capable of gen-
erating high serum concentrations of a desired monoclo-
nal antibody in mice following a single intramuscular
injection of a specialized adeno associated viral vector
(AAV). Mice that received VIP encoding b12 and VRC01
antibodies demonstrated long-term circulating antibody
expression in serum, and VIP-treated humanized mice
exhibited remarkable protection against high dose, intrave-
nous challenge with CXCR4-tropic HIV. However, most
human infections are initiated by transmission of CCR5-
tropic strains through mucosal tissues.
Methods
To measure the efficacy of VIP against clinically relevant
strains, we humanized VIP-treated mice by adoptive trans-
fer of peripheral blood mononuclear cells (PBMC) and
challenged these animals with CCR5-tropic HIV strains
including JR-CSF, as well as REJO.c, a transmitted molecu-
lar founder. To determine the ability of VIP to prevent
mucosal transmission of HIV, we developed a repetitive
intravaginal challenge model in VIP-treated BLT huma-
nized mice that were challenged weekly with JR-CSF and
monitored for infection.
Results
PBMC humanized mice expressing either b12 or VRC01
were protected from intravenous challenge with JR-CSF.
In contrast, the b12-resistant REJO.c strain readily infected
PBMC humanized mice expressing b12 antibody, while
mice expressing VRC01 demonstrated nearly complete
protection following challenge. Intravaginally challenged
BLT animals expressing a luciferase negative control pro-
tein all became infected over the study period while a
majority of animals expressing VRC01 had no detectable
HIV infection despite fourteen intravaginal challenges
with JR-CSF.
Conclusion
VIP is capable of protecting humanized mice from chal-
lenge by diverse HIV strains and can substantially inhibit
mucosal transmission. These findings warrant continued
development of VIP as a novel approach for HIV preven-
tion in humans.
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